Informe nº Osteba D12-04. - Euskadi.net

ESTRATEGIAS TERAPÉUTICAS EN LA ESQUIZOFRENIA REFRACTARIA O ESQUIZOFRENIA RESISTENTE AL TRATAMIENTO55. Heresco-Levy U, Javitt DC, Ermilov M, MordelC, Silipo G, Lichtenstein M. Efficacy of highdoseglycine in the treatment of enduringnegative symptoms of schizophrenia. ArchGen Psychiatry. 1999; 56: 29–36.56. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL,Bartone P, Cooley S, Hammill K, Carter M, MunetzMR, Perel J. PharmacotherapyPsychiatry. 1995; 52: 29–41.57. Hinkes R, Quesada TV, Currier MV, GonzalezBlanco M. Aspiration pneumonia possibly secondaryto clozapine-induced sialorrea (letter).J Clin Psychopharmacol. 1996; 16:462-463.58. Hirsch S, Weinberger D. Schizophrenia 2thedition. (Ed Blackwell Science). 2003.59. Honigfeld G, Arellano F, Sethi J, Bianchini A,Eschein J. Reducing clozapina-related morbidituand mortality: 5 years experience withthe Clozaril national registry. J ClinPsychiatry. 1998; 59 Suppl. 3: 3-7.60. Iqbal MM, Rahman A, Husain Z, MahmudSZ, Ryan WG, Feldman JM. Clozapine: a clinicalreview of adverse effects and management.Ann Clin Psychiatry. 2003; 15:33-48.61. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negativesymptoms in schizophrenia byglycine. Am J Psychiatry. 1994; 151: 1.234–1.236.62. Javitt DC, Silipo G, Cienfuegos A, Shelley AM,Bark N, Park M, Lindenmayer JP, Suckow R,Zukin SR. Adjunctive high-dose glycine inthe treatment of schizophrenia. Int J Neuropsychopharmacol.2001; 4: 385–391.63. Kando JC, Tohen M, Castillo J, Centorrino F.Concurrent use of clozapine and valproate inaffective and psychotic disorders. J ClinPsychiatry. 1994; 55(6): 255-7.64. Kane J, Honigfeld G, Singer J, Meltzer H, andthe clozaril collaborative study group Clozapinefor the treatment-resistant schizophrenic.A duble-blind comparison withclozapina. Arch Gen Psychiatry. 1988; 45:789-796.65. Kane JM, Leucht S, Carpenter D, Docherty JP.Expert Consensus Panel for Optimizing PharmacologicTreatment of Psychotic Disorders.The expert consensus guideline series. Optimizingpharmacologic treatment of psychoticdisorders. Introduction: methods,commentary, and summary. J Clin Psychiatry.2003; 64 (Suppl 12): 5-19.66. Keefe R, Silva S, Perkins D. The effects of atypicalantipsychotic drugs on neurocognitiveimpairment in schizophrenia: a review andmeta-analysis. Schizophr Bull. 1999; 25: 201-222.67. Kellner M, Wiedermann K, Krieg JC, Berg PA.Toxic hepatitis by clozapina treatment (letter).Am J Psychiatry. 1993; 150: 985-986.68. Kilian JG, Kerr K, Lawrence C, Celermajer DS.Myocarditis and cardiomyopathy associatedwith clozapine. Lancet. 1999; 354 (9.193):1.841-5.69. Klein DF, Davis JM. Diagnosis and Drug Treatmentof Psychiatric Disorders. Baltimore:Williams & Wilkins. 1969.70. Kontaxakis V P, Ferentinos PP, Havaki-KontaxakiBJ, Roukas DK. Randomized controlledaugmentation trials in clozapine resistantschizophrenic patients: a critical review. EurPsychiatry. 2005; 20: 409-415.71. Kremer I, Vass A, Gorelik I, Bar G, Blanaru M,Javitt DC et al. Placebo-controlled trial of lamotrigineadded to conventional and atypicalantipsychotics in schizophrenia. BiolPsychiatry. 2004; 56(6): 441-6.72. Kronig MH, Munne RA, Szymanski S, SaffermanAZ, Pollack S, Cooper T, Kane JM, LiebermanJA. Plasma clozapine levels and clinicalresponse for treatment-refractory schizophrenicpatients. Am J Psychiatry. 1995; 152:179-182.73. Krupp P, Barnes P. Leponex-associated granulocitopenia:a review of the situation.Psychopharmacology. 1989; 99 (Suppl.): 118-121.74. Kurz M, Hummer M, Oberbauer H et al. Extrapyramidalside effects of clozapine and112